Oral GLP-1 Medications: What Weight Loss Patients Should Know

By Ann Czarnik, M.D., Board-Certified Emergency Medicine Physician and Co-Founder, Amanecia Health

For the past two years, GLP-1 medications have changed the way physicians approach weight management. Semaglutide and tirzepatide, delivered as weekly injections, have helped millions of patients achieve meaningful, sustained weight loss under medical supervision.

Now there is a new chapter. Two oral GLP-1 medications have received FDA approval for weight management, and both are available to patients right now. This changes the conversation for anyone who has been interested in medical weight loss but uncomfortable with injections, or for patients who have already reached their goal weight and want a simpler maintenance option.

Here is what you need to know.

Two Oral Options, Different Approaches

The FDA approved oral semaglutide (the Wegovy pill, made by Novo Nordisk) in late 2025, followed by orforglipron (Foundayo, made by Eli Lilly) on April 1, 2026. Both are GLP-1 receptor agonists taken as a daily pill instead of a weekly injection.

They are not identical.

Oral semaglutide is the same active compound found in injectable Wegovy. Clinical trials showed average weight loss of approximately 16.6% at the highest dose over 72 weeks. It must be taken first thing in the morning on an empty stomach with no more than four ounces of water. Then you wait at least 30 minutes before eating, drinking, or taking any other medications. That means no coffee, no breakfast, and no morning pills until the window passes. For some patients, that daily routine is easy. For others, it is a real barrier.

Foundayo (orforglipron) is a different molecule entirely. It is a small-molecule GLP-1 agonist, not a peptide. That distinction matters because it can be taken at any time of day, with or without food, with no water restrictions. Clinical trials showed average weight loss of approximately 12.4% at the highest dose over 72 weeks. It is available through LillyDirect and will be in retail pharmacies shortly.

Both pills are less potent than the injectable versions. Tirzepatide injections (Zepbound) have shown weight loss exceeding 20% in clinical trials. The tradeoff is convenience and accessibility.

There is also a compliance question worth discussing with your physician. A weekly injection is one decision, once a week. A daily pill requires consistency every single day. If you miss a couple of doses a week, the medication is less effective. For patients with structured routines, a daily pill may fit easily. For others, the weekly injection they already tolerate may actually be the more reliable option. This is not a universal upgrade from injection to pill. It is a different tool with different tradeoffs, and the right choice depends on how you live your life, not just how you feel about needles.

What This Means for Our Patients

At Amanecia Health, we already offer multiple pathways for GLP-1 weight loss treatment: brand-name injectables through LillyDirect and retail pharmacies, and compounded formulations through our licensed compounding partners.

Adding oral GLP-1 medications expands the options we can offer in two important ways.

First, for patients who are interested in medical weight loss but have been hesitant about injections. Some patients simply do not want a needle. That is a valid preference, and until now it meant GLP-1 therapy was not an option for them. Oral formulations change that.

Second, and this is where our physicians are particularly interested, as a maintenance tool. Many patients achieve their target weight on injectable GLP-1 medications and then face a difficult question: what happens when I stop? The data consistently shows that patients who discontinue GLP-1 therapy regain weight. Oral GLP-1 medications offer a potential bridge. A patient could lose weight on a more potent injectable, then transition to a daily pill for long-term maintenance at a lower dose and lower cost.

Dr. Lauren Leavitt, who leads our Houston practice, has already been coordinating oral GLP-1 access through LillyDirect for several current patients. As she put it: “It offers a wonderful alternative for patients who may be uncomfortable with injections or are seeking a more seamless maintenance routine. An informed, collaborative decision-making process remains at the heart of our care.”

Dr. Kelsey English, who serves our Dallas-Fort Worth patients, sees the maintenance angle as the biggest opportunity: “Everyone on GLP-1s has concerns about weaning off. This adds another option for them to maintain a goal weight.”

Dr. Nora Demchur, a board-certified Emergency Medicine physician who practices with Amanecia in Austin, sees the oral options fitting a specific gap in patient care. “I have patients who are excellent candidates for GLP-1 therapy but have put it off because they do not want a weekly injection. For those patients, having a pill that works through the same mechanism removes the one barrier that was keeping them from getting started. That is a meaningful clinical win.”

How Prescribing Works

Oral GLP-1 medications are prescription medications. They are not available over the counter. A licensed physician must evaluate whether you are an appropriate candidate based on your BMI, health history, current medications, and treatment goals.

At Amanecia Health, the process is the same as our injectable GLP-1 program. You start with a comprehensive evaluation, either via telemedicine or an in-home visit. Your physician reviews your metabolic profile, discusses your goals, and determines which medication and delivery method is right for you. If oral GLP-1 therapy is clinically appropriate, we prescribe it and coordinate with your pharmacy or through LillyDirect for home delivery.

Follow-up visits happen on a regular schedule. Your physician monitors your progress, manages side effects, adjusts dosing, and helps you make the dietary and lifestyle changes that support long-term results.

This is not a prescription mill. You are not filling out an online form and receiving a pill in the mail from someone you have never met. You have a physician who knows your history and stays involved in your care.

Pricing and Access

One of the most significant changes with oral GLP-1 medications is cost.

Both Foundayo and the Wegovy pill start at $149 per month for the lowest dose for self-pay patients. Higher doses cost more, up to approximately $349 per month. Patients with commercial insurance may pay as little as $25 per month with manufacturer savings cards.

For context, injectable GLP-1 medications without insurance have historically cost $1,000 or more per month at retail. Compounded formulations are more affordable, typically in the $200 to $400 range depending on the medication and dose. The oral options at $149 starting represent a meaningful expansion of access.

We continue to offer compounded semaglutide and tirzepatide as part of our weight loss program. The best option depends on your clinical situation, your goals, and your preferences. That is exactly the kind of decision your physician helps you make.

Side Effects

The side effect profile for oral GLP-1 medications is similar to the injectables. The most common side effects are gastrointestinal: nausea, constipation, diarrhea, and stomach discomfort. These typically improve over time and can be managed with proper dose titration, which is one of the reasons physician oversight matters.

Both medications carry a boxed warning regarding thyroid C-cell tumors and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Your physician will review your full health history before prescribing any GLP-1 medication, oral or injectable.

What to Do Next

If you are a current Amanecia patient interested in adding an oral GLP-1 option to your treatment plan, or transitioning from an injectable to an oral maintenance medication, bring it up at your next visit or reach out to your physician directly. We are already prescribing these medications for appropriate patients.

If you are new to Amanecia and interested in medical weight loss, whether with oral or injectable GLP-1 medications, the first step is a consultation with one of our physicians. We will evaluate your health profile, discuss all available options, and build a plan that fits your goals.

Schedule a consultation

Frequently Asked Questions

Are oral GLP-1 medications as effective as the injections?
Oral GLP-1 medications produce meaningful weight loss but typically less than the injectable versions. Oral semaglutide showed approximately 16.6% average weight loss at the highest dose. Foundayo showed approximately 12.4%. Injectable tirzepatide has shown over 20%. Your physician can help determine which option best fits your goals.

Can I switch from an injection to a pill?
Yes. Clinical data shows that patients who transition from injectable GLP-1 therapy to an oral formulation can maintain their weight loss. This is one of the most promising applications of oral GLP-1 medications, as a maintenance tool after reaching your target weight on a more potent injectable.

Do I need a prescription for oral GLP-1 pills?
Yes. Oral GLP-1 medications are prescription-only. A physician must evaluate your health profile, including BMI, medical history, and current medications, before prescribing.

How much do oral GLP-1 medications cost?
Self-pay pricing starts at $149 per month for the lowest dose of both Foundayo and oral Wegovy. Higher doses cost more. Patients with commercial insurance may qualify for savings programs that reduce the cost to as low as $25 per month.

Can I take Foundayo with food?
Yes. Foundayo can be taken at any time of day with or without food. This is different from the Wegovy pill, which must be taken on an empty stomach first thing in the morning with no more than four ounces of water, followed by a 30-minute wait before eating, drinking, or taking other medications.

What are the side effects of oral GLP-1 pills?
Side effects are similar to injectable GLP-1 medications. The most common are nausea, constipation, diarrhea, and stomach discomfort. These typically improve with proper dose titration over time.

Ann Czarnik, M.D. is a board-certified Emergency Medicine physician with over 20 years of clinical experience and co-founder of Amanecia Health. She practices in Austin, TX, with Amanecia locations also in Houston, Dallas-Fort Worth, and Coastal Virginia.

Find an Amanecia physician near you.

Oral GLP-1 Medications Are Here. What Patients Should Know.